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الكربى
مرت�شى خمي�س اخلابوري، اأروى الريامية، خليل الفار�شي، حممد احلنيني، عبداحلكيم الها�شم، نا�رص الكمياين، عي�شى القر�شوبي، حماد خان، خلفان 
العمراين، �شاهينا داعر
abstract: Objectives: This study aimed to validate pulse CO-oximetry-based haemoglobin (Hb) estimation in 
children and adults with thalassaemia major (TM) and to determine the impact of different baseline variables on 
the accuracy of the estimation. Methods: This observational study was conducted over a five-week period from 
March to April 2012. A total of 108 patients with TM attending the daycare thalassaemia centre of a tertiary care 
hospital in Muscat, Oman, were enrolled. Spot (Sp) Hb measurements were estimated using a Pronto-7® pulse 
CO-oximetry device (Masimo Corp., Irvine, California, USA). These were compared to venous samples of Hb using 
the CELL-DYN Sapphire Hematology Analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA) to determine 
the reference (Ref ) Hb levels. A multivariable linear regression model was used to assess the impact of baseline 
variables such as age, gender, weight, height, Ref Hb and blood pressure on the Hb estimations. Results: Of the 108 
enrolled patients, there were 54 males and 54 females with a mean age of 21.6 years (standard deviation [SD] = 7.3 
years; range: 2.5–38 years). The mean Ref Hb and Sp Hb were 9.4 g/dL (SD = 0.9 g/dL; range: 7.5–12.3 g/dL) and 
11.1 g/dL (SD = 1.2 g/dL; range: 7.5–14.7 g/dL), respectively. The coefficient of determination (R2) was 21% with 
a mean difference of 1.7 g/dL (SD = 1.1 g/dL; range: −0.9–4.3 g/dL). In the multivariable model, the Ref Hb level 
(P = 0.001) was the only statistically significant predictor. Conclusion: The Pronto-7® pulse CO-oximetry device 
was found to overestimate Hb levels in patients with TM and therefore cannot be recommended. Further larger 
studies are needed to confirm these results.
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لدى  النب�شي  التاأك�شج  قيا�س  بطريقة  الهيموجلوبني  تركيز  م�شتوى  تقدير  �شحة  من  التحقق  اإىل  الدرا�شة  هذه  تهدف  الهدف:  امللخ�ص: 
الأطفال والبالغني امل�شابني مبر�س الثال�شيميا الكربى. الطريقة: اأجريت هذه الدرا�شة الو�شفية على مدى خم�شة اأ�شابيع خالل الفرتة من 
مار�س اإىل اأبريل 2012. و�شملت الدرا�شة 108 مر�شى بالثال�شيميا الكربى املراجعني للعيادة النهارية مبركز الثال�شيميا يف م�شت�شفى 
 Pronto-7® مرجعي مب�شقط، �شلطنة عمان. مت قيا�س م�شتوى تركيز الهيموجلوبني لكل مري�س بطريقة التاأك�شج النب�شي بوا�شطة جهاز
)�رصكة ما�شيمو، اإرفني، كاليفورنيا، الوليات املتحدة الأمريكية( ثم مقارنتها بقيا�س الهيموجلوبني يف عينة دم وريدي بوا�شطة جهاز
CELL-DYN Sapphire Hematology Analyzer )�رصكة اأبوت، اأبوت بارك، اإلينوي�س، الوليات املتحدة الأمريكية( لتحديد 
الهيموجلوبني املرجعي. ا�شتمل منوذج النحدار اخلطي متعدد املتغريات لتوقع تقدير الختالفات على املتغريات التالية: العمر واجلن�س 
والوزن والطول وقيا�س �شغط الدم والهيموجلوبني املرجعي. النتائج: �شملت الدرا�شة 108 مر�شى ن�شفهم من الذكور والن�شف الآخر من 
الإناث وكان متو�شط العمر 21.6 �شنة )النحراف املعياري 7.3 �شنة؛ النطاق 38-2.5 �شنة(. وكان متو�شط تركيزالهيموجلوبني املرجعي 
اأما متو�شط تركيزالهيموجلوبني  غرام/دي�شيليرت(   7.5-12.3 النطاق  0.9 غرام/دي�شيليرت؛  )النحراف املعياري  9.4 غرام/دي�شيليرت 
بطريقة التاأك�شج النب�شي فكان 11.1 غرام/دي�شيليرت )النحراف املعياري 1.2 غرام/دي�شيليرت؛ النطاق 14.7-7.5 غرام/دي�شيليرت(. 
واأما معامل التعيني )R2( فكان %21 مع متو�شط فارق وقدره 1.7 غرام/دي�شيليرت )النحراف املعياري 1.1 غرام/دي�شيليرت؛ النطاق 
4.3-0.9 غرام/دي�شيليرت(. ويف منوذج متعدد املتغريات كان م�شتوى تركيز الهيموجلوبني )P = 0.001( هو العامل املتنبئ الوحيد ذو 
دللة اإح�شائية معنوية. اخلال�صة: يبالغ جهاز التاأك�شج النب�شي ®Pronto-7 يف قيا�س م�شتوى تركيز الهيموجلوبني ملر�شى الثال�شيميا 
الكربى. ولذا ل نن�شح با�شتخدامه يف هذه ال�رصيحة من املر�شى. ونن�شح باإجراء درا�شات اأكرب للتثبت من هذه النتائج.
مفتاح الكلمات: الثال�شيميا الكربى؛ درا�شات التحقق؛ هيموجلوبني؛ التاأك�شج النب�شي.
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Advances in Knowledge
- This study found that the investigated CO-oximetry device (Pronto-7® Pulse, Masimo Corp., Irvine, California, USA) overestimates 
haemoglobin levels in patients with thalassaemia major (TM).
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Thalassemia major (TM) is a relatively common inherited blood disorder that is prevalent among the population of Oman. 
It results from the homozygous loss of beta-globin 
gene expression and presents in childhood with 
impaired growth and a failure to thrive.1,2 Those 
affected need regular, adequate blood transfusions 
in order to maintain normal growth and to prevent 
extramedullary haematopoiesis which leads to the 
skeletal abnormalities typically seen in TM-affected 
individuals.3–5
Patients with TM are able to tolerate low 
haemoglobin (Hb) levels without showing the typical 
symptoms of anaemia and, as a result, the parents 
of young TM patients do not always realise the 
importance of maintaining adequate Hb levels. It was 
hypothesised that regular non-invasive spot (Sp) Hb 
measurements would improve transfusion planning 
for TM patients and optimise the prevention of 
extramedullary haematopoiesis, along with the related 
skeletal abnormalities of this condition. 
The portable Pronto-7® device (Masimo Corp., 
Irvine, California, USA) has been previously 
evaluated as a non-invasive method for assessing 
Hb levels via pulse CO-oximetry Hb estimation.6‒9 
Additionally, a former study validated the use of Sp 
Hb measurements in patients with sickle cell disease 
(SCD) and in normal blood donors.10,11 Research has 
also shown that the Pronto-7® device, which is based 
on spectrophotometry,12 could be used effectively as a 
continuous Hb monitor to assess trends in Hb levels 
among patients in intensive care settings.8 However, 
the use of this device in TM patients with lower Hb 
levels has not previously been examined and the 
ability of the device to accurately estimate Sp Hb levels 
in this patient group has yet to be validated. The aim 
of this study, therefore, was to validate the pulse CO-
oximetry-based method of Hb estimation in patients 
with TM and to assess the impact of different baseline 
variables on the accuracy of the estimation. 
Methods 
This observational study involved 108 patients with 
TM from the thalassaemia daycare unit of the Sultan 
Qaboos University Hospital (SQUH) in Muscat, Oman. 
The study was conducted over a five-week period from 
March to April 2012 and included participants of all 
ages and both genders. The diagnosis of TM was based 
on the absence of Hb A via high-performance liquid 
chromatography in patients requiring regular blood 
transfusions. 
Two spot Hb measurements (Sp1 Hb and Sp2 Hb) 
were taken 10 minutes apart using small, medium and 
large Rainbow® reusable spot check sensors (Masimo 
Corp.), for patients weighing 10 to 50 kg. These were 
connected to the Pronto-7® pulse CO-oximetry device 
according to the manufacturer’s recommendations. In 
addition, a venous sample was taken in order to make 
a laboratory-based Hb estimation and determine the 
patients’ reference (Ref ) Hb levels. For this purpose, 
the CELL-DYN Sapphire Hematology Analyzer 
(Abbott Laboratories, Abbot Park, Illinois, USA), 
was used, as this is considered the gold standard for 
accurately recording Hb levels.13 
Continuous variables were presented as means 
with standard deviations and ranges, while categorical 
variables were shown as frequencies and percentages. 
Scatter plots were used to compare the continuous 
variables (Ref Hb versus Sp1 Hb and Sp1 Hb versus Sp2 
Hb). A linear regression model was used to estimate 
the intercept, the beta coefficients and the coefficient 
of determination (R2). The R2 value was used as an 
estimate of goodness-of-fit and the two methods of 
Hb estimation were compared using a Bland-Altman 
plot. Multivariable linear regression was used to assess 
the impact of selected baseline characteristics (age, 
gender, weight, height, Ref Hb and blood pressure) on 
the difference between the Sp1 Hb and Ref Hb levels. 
An alpha error threshold of 0.05 was considered for 
statistical significance. The statistical software Stata, 
Version 11 (StataCorp LP, College Station, Texas, 
USA) was used for all descriptive statistics, graphs and 
analytical tests. 
The study protocol was reviewed and approved 
by the Medical Research & Ethics Committee at the 
College of Medicine & Health Sciences, Sultan Qaboos 
University (MREC#506). All patients gave informed 
consent after being briefed by a trained medical officer 
or nurse.
Results 
A total of 108 patients (54 male and 54 female) with 
TM were enrolled in this study, with a mean age of 
21.6 ± 7.3 years (range: 2.5–38 years). Only 10% of 
Application to Patient Care
- The results of this study indicate that this pulse CO-oximetry device should not be used for the purpose of haemoglobin estimation in 
TM patients as it was found to overestimate haemoglobin levels among this patient population.
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the patients were aged 11 years or younger. The mean 
Ref Hb, Sp1 Hb and Sp2 Hb levels were 9.4 ± 0.9 g/
dL (range: 7.5–12.3 g/dL), 11.1 ± 1.2 g/dL (range: 
7.5–14.7 g/dL) and 10.8 ± 1.2 g/dL (range: 7.5–14.2 g/
dL), respectively. The mean weight and height of the 
participants were 52.4 ± 16.4 kg (range: 12.8–100.7 kg) 
and 154 ± 15 cm (range: 88–184 cm), respectively. The 
mean blood pressure of the patients was 111/66 ± 13/9 
mmHg (range: 80/47–138/100 mmHg) [Table 1].
The scatter plot of Sp1 Hb versus Ref Hb is shown 
in Figure 1, with an R2 of 21%. The mean difference 
between Sp1 Hb and Ref Hb was 1.7 ± 1.1 g/dL (range: 
−0.9–4.3 g/dL). A Bland-Altman plot of the differences 
in estimation between Sp Hb and Ref Hb levels 
indicated that most of the variations were greater than 
1 g/dL [Figure 2], indicating that the Pronto-7® pulse 
CO-oximetry device overestimated the patients’ Hb 
levels. The upper and lower limits of agreement were 
3.8 and −0.4 g/dL, respectively. In the multivariable 
model, Ref Hb level was the only statistically significant 
predictor of the difference (P = 0.001). The R2 of the 
two CO-oximetry Hb measurements, which were 
taken 10 minutes apart, was 46% [Figure 3].
Discussion 
The Pronto-7® pulse CO-oximetry device was found 
to overestimate the Hb level in TM patients by a 
mean of 1.7 g/dL, with clinically unacceptable limits 
of agreement. The use of this device in estimating Hb 
levels, therefore, cannot be recommended for this 
group of patients. The only significant predictor for 
this discrepancy in estimation was the Ref Hb level, 
which was assessed using a gold standard method. The 
reproducibility of the estimation remained high when 
 
Figure 1: Scatter plot showing reference haemoglobin 
(Hb) versus spot Hb levels estimated by a pulse CO-
oximetry device among patients with thalassaemia 
major (N = 108).
Ref Hb = reference haemoglobin; Sp Hb = spot haemoglobin; CI = 
confidence interval.
 
Figure 2: Distribution of the differences between spot 
(Sp) haemoglobin (Hb) levels estimated by a pulse CO-
oximetry device and reference (Ref ) Hb levels among 
patients with thalassaemia major (N = 108). The y-axis 
shows the difference between Sp Hb and Ref Hb (Sp Hb 
– Ref Hb) and the x-axis shows the value of the Ref Hb. 
The three continuous lines represent the differences at 
+1, 0 and -1 (starting from the top). 
Ref Hb = reference haemoglobin; Sp Hb = spot haemoglobin.
 
Figure 3: Scatter plot of two spot haemoglobin 
measurements by the CO-oximetry device among 
patients with thalassaemia major (N = 108).
Sp Hb = spot haemoglobin; CI = confidence interval.
Table 1: Baseline characteristics among patients with 
thalassaemia major (N = 108)
Variable Mean value
Age in years 21.6 ± 7.3
Male: female ratio* 54:54
Ref Hb in g/dL 9.4 ± 0.9
Spot 1 Hb in g/dL 11.1 ± 1.2
Spot 2 Hb in g/dL 10.8 ± 1.2
Weight in kg 52.4 ± 16.4
Height in cm 154 ± 15
BP in mmHg 111/66 ± 13/9
Ref = reference; Hb = haemoglobin; BP = blood pressure.
*This value is not expressed as mean ± standard deviation.
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the test was repeated after a short interval. 
A spectrum bias is a common problem in 
diagnostic studies, leading to a false increase in the 
sensitivity and specificity of new diagnostic tests.14 
Previous studies have demonstrated the validity of 
the Pronto-7® pulse CO-oximetry device for use in 
normal blood donors and in patients with SCD.10,11 
In contrast, the current study observed that the same 
device overestimates Hb levels in TM patients by a 
clinically significant margin. The difference in the 
validation results may potentially be due to the lower 
Hb levels commonly seen in patients with TM; these 
lower HB levels are not frequently observed among 
patients with SCD or in normal blood donors. The 
use of this device is therefore not recommended in 
patients with low Hb levels, for instance among those 
suspected of being anaemic.
Another reason why different validation results 
were observed in the current study may be due to 
variations within the chosen patient populations. The 
present study included paediatric patients, whereas 
the previous studies investigating blood donors and 
patients with SCD did not.10,11 In the study investigating 
blood donors, differences in height may have been 
partially responsible for the different estimates.10 This 
is because the three different sizes of sensor may not 
have been optimal in terms of fit for certain patients 
with different heights. In the two previous studies, 
as well as the current study, the same sized sensors 
were used.10,11 However, if the fit of the sensor was 
not optimal on all patients, this could have affected 
the accuracy of the estimates produced, leading to a 
larger difference between estimates. In the current 
study, the age and height of the participants were not 
found to be statistically significant enough to explain 
the difference in estimates. It is possible that modelling 
the interaction between patients’ heights or ages and 
differing Hb estimates may shed further light on the 
issue; this was not carried out in the present study due 
to the complexity of such modelling and the relatively 
small sample size.
Although different conclusions were drawn with 
regards to the validity of the pulse CO-oximetry device, 
it is interesting to note that similar findings were noted 
between the current study and the previous studies 
in the numerical estimates of the studied subjects, 
when comparing the R2.10,11 In validation studies, it 
is important that any conclusions drawn should not 
be based on a single parameter, but instead take into 
consideration all available parameters, the limitations 
of each and the fact that these complement each other. 
In the current study, the Bland-Altman plot showed 
the distribution of the difference between estimations 
and revealed the bias of overestimation in the Sp Hb 
levels compared with the Ref Hb levels. The standard 
methodology of the present study has many merits 
and is frequently utilised in diagnostic studies.15
In light of its limitations, the results of this study 
should be interpreted with caution. There was a 
limited supply of sensor sizes, although every attempt 
was made among individual patients to choose the 
finger with the best physical fit for the sensor used. 
The fact that only three sizes of sensors were available 
for use (small, medium or large), without taking 
into consideration the need for other sizes among 
the patients, likely biased the difference between 
estimations to be larger than the true value. Moreover, 
the inclusion of both children and adults in one study 
may have increased the variance and decreased the 
power, making it difficult to truly show the validity 
of the device. High levels of fetal Hb in children may 
have interfered with the measurement accuracy of the 
device.16 Additionally, as the majority of the patients 
in the study were adults, the conclusions drawn 
from this study cannot be generalised to paediatric 
patients, although the authors would still caution 
the use of this device in children. Paediatric patients 
were included in this study so as to assess this device 
among the age group that may potentially benefit 
the most from its use. Furthermore, it should be 
noted that previous research has indicated that the 
Pronto-7®’s performance was satisfactory when used 
as a continuous monitor, rather than a single spot 
measurement as in the present study.8 Finally, the 
study was also limited by its relatively small sample 
size, which decreased the power to detect significant 
factors to predict the discrepancy in Hb estimates. 
The study has a number of strengths despite the 
above limitations. Foremost, this is the first and only 
study to specifically address the population of TM 
patients. This study included patients with Hb levels as 
low as 7.5 g/dL, although patients with TM can have 
levels lower than this. In addition, the biased estimate 
found in this evaluation of the Pronto-7® device calls 
for caution in the interpretation of diagnostic studies 
with potential spectrum bias. 
Conclusion 
The results of this study demonstrate that the 
Pronto-7® pulse CO-oximetry device overestimates 
the haemoglobin level in patients with TM, and 
therefore cannot be recommended for use with this 
group. The authors further caution the use of this 
device in children and in patients suspected of being 
anaemic. Studies with larger patient populations are 
needed to confirm these results. 
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